Quantized Acoustoelectric Floquet Effect in Quantum Nanowires.

External coherent fields can drive quantum materials into nonequilibrium states, revealing exotic properties that are unattainable under equilibrium conditions-an approach known as "Floquet engineering." While optical lasers have commonly been used as the driving fields, recent advancements have introduced nontraditional sources, such as coherent phonon drives. Building on this progress, we demonstrate that driving a metallic quantum nanowire with a coherent wave of terahertz phonons can induce an electronic steady state characterized by a persistent quantized current along the wire.

HPV genotype-specific prevalence and infection risks: A 10-year population-based study from the United States.

Background: Various studies have reported on the impact of human papillomavirus (HPV) vaccines. Here we present the largest population-based investigation of genotype-specific distributions over the decade following implementation of the 4-valent HPV vaccine (HPV6/11/16/18) in the United States.

Methods: Liquid-based cervical cytology samples from individuals aged 15-30 years undergoing cervical screening throughout New Mexico were tested by broad-spectrum HPV genotyping.

Perception and participation in sport and exercise in cystic fibrosis: The impact of CFTR modulators.

Background: People with cystic fibrosis (pwCF) have barriers to physical activity including exercise intolerance and fatigue. The advent of small molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulators have shown great clinical improvements in pwCF; however, the effect of CFTR modulators on exercise perception and participation is unknown. The purpose of this study was to investigate whether the administration of CFTR modulators changed the perception and participation in sport and exercise in pwCF.

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR in the USA: a prospective, multicentre, open-label, single-arm trial.

Background: CFTR modulators are approved for approximately 90% of people with cystic fibrosis in the USA and provide substantial clinical benefit. N1303K (Asn1303Lys), one of the most common class 2 CFTR defects, has not been approved for these therapies by any regulatory agency. Preclinical investigation by our laboratories showed N1303K CFTR activation with elexacaftor-tezacaftor-ivacaftor (ETI).